Harald Duerr

USPTO Granted Patents = 13 (Patent Applications = 17)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 13)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 62(Granted Patents)

Location History:

Penzberg, DE (2022 - 2023)
Starnberg, DE (2017 - 2024)

Company Filing History:

9 out of 4,942

Hoffmann-la Roche Inc.

where one patent can have more than one assignee

Years Active: 2017-2025

where 'Filed Patents' based on already Granted Patents

13 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358997 - Bispecific anti-human A-beta/anti-human transferrin receptor antibodies (2025-07-15),

2. 12275794 - Bispecific antigen binding molecules comprising anti-FAP clone 212 (2025-04-14),

3. 12145994 - Bispecific antigen binding molecules capable of specific binding to CD40 and to fap (2024-11-19),

4. 12030952 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2024-07-09),

5. 11787868 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2023-10-17),

6. 11780919 - Bispecific antigen binding molecules targeting OX40 and FAP (2023-10-10),

7. 11603411 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2023-03-14),

8. 11242396 - Bispecific antigen binding molecules comprising anti-FAP clone 212 (2022-02-08),

9. 10941205 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2021-03-09),

10. 10683345 - Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases (2020-06-16),

11. 10316059 - Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography (2019-06-11),

12. 10106600 - Bispecific antibodies (2018-10-23),

13. 9695233 - Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases (2017-07-04),

Title: The Innovative Contributions of Harald Duerr

Introduction

Harald Duerr is a prominent inventor based in Starnberg, Germany, known for his significant contributions to the field of biotechnology. With a total of 13 patents to his name, Duerr has made remarkable advancements in the development of bispecific antibodies and antigen binding molecules.

Latest Patents

Among his latest patents, Duerr has developed bispecific anti-human A-beta/anti-human transferrin receptor antibodies. This invention provides methods for utilizing these antibodies in various applications. Additionally, he has created bispecific antigen binding molecules that comprise anti-Fibroblast Activation Protein (FAP) clone 212. This invention relates to novel molecules that can specifically bind to FAP and CD40, along with methods for producing and using these innovative compounds.

Career Highlights

Throughout his career, Duerr has worked with notable companies in the biotechnology sector, including Hoffmann-La Roche Inc. and Roche Glycart AG. His work in these organizations has contributed to the advancement of therapeutic solutions in the medical field.

Collaborations

Duerr has collaborated with esteemed colleagues such as Christian Klein and Joerg Thomas Regula. These partnerships have fostered innovation and have been instrumental in the development of his groundbreaking inventions.

Conclusion

Harald Duerr's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence advancements in medical therapies and antibody development.

This text is generated by artificial intelligence and may not be accurate.